Related Experiment Video
Updated: Feb 12, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Enhancing therapeutic outcomes with artificial intelligence for HR-positive, HER2-negative metastatic breast cancer
Juan Luis Gomez Marti1, Elena Michaels2, Azadeh Nasrazadani3
1Northwell Health, New Hyde Park, NY, USA; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract:
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are an integral first-line treatment for hormone receptor-positive metastatic breast cancer, though resistance eventually develops. In this issue of Cancer Cell, Fan et al. report results from LINUX, a randomized phase 2 trial applying an artificial intelligence digital pathology classification system to guide therapy after CDK4/6i progression.
Insights
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are crucial for metastatic breast cancer but resistance occurs. A phase 2 trial used AI digital pathology to guide therapy after CDK4/6i treatment failure.
Area of Science:
- Oncology
- Translational Research
- Artificial Intelligence in Medicine
Background:
- Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) represent a cornerstone of first-line therapy for hormone receptor-positive (HR+) metastatic breast cancer.
- Acquired resistance to CDK4/6i is an inevitable challenge, necessitating novel therapeutic strategies post-progression.
Purpose of the Study:
- To evaluate the efficacy of an artificial intelligence (AI) digital pathology classification system in guiding treatment selection following CDK4/6i progression in HR+ metastatic breast cancer.
- To assess the clinical utility of AI-driven therapeutic guidance in a randomized trial setting.
Main Methods:
- The LINUX trial was a randomized phase 2 study.
- An AI digital pathology classification system was employed to analyze tumor characteristics after CDK4/6i failure.
- Therapeutic strategies were guided by the AI classification system in the experimental arm.
Main Results:
- The study reported on the outcomes of patients treated based on AI-guided therapy post-CDK4/6i progression.
- Specific efficacy data and treatment response rates associated with the AI-guided approach were presented.
Conclusions:
- Artificial intelligence digital pathology shows promise as a tool to personalize treatment strategies in metastatic breast cancer after CDK4/6i resistance.
- The LINUX trial provides evidence for the potential of AI to optimize therapeutic decisions in this patient population.
More Related Videos
Related Concept Videos
Positive, Negative, and Zero Work
Positive and Negative Feedback Loops
Intelligence
Self-Evaluation: Self-Enhancement and Self-Verification
Predicting Reaction Outcomes
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...

